🔎 Trials Near Me

Home › Ependymoma

Ependymoma clinical trials recruiting in the U.S.

15 studies for Ependymoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

RecruitingPhase 2
Up to age 19 · All sexes · Updated Sep 10, 2026 · NCT01356290

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388

B7-H3.CD28Z.CART in CNS Neoplasms

RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT04374305

Natural History Study of Patients With Neurofibromatosis Type 2

RecruitingObservational study
Ages 8 to 75 · All sexes · Updated Sep 1, 2026 · NCT00598351

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Aug 12, 2026 · NCT06161519

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Recruiting
12 Months – 39 Years · All sexes · Updated Aug 11, 2026 · NCT05057702

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jun 17, 2026 · NCT06193759

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Jun 11, 2026 · NCT04732065

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

RecruitingPhase 1
Up to age 22 · All sexes · Updated May 20, 2026 · NCT03750513

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Jan 9, 2026 · NCT05106296

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT04541082

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.